Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
StemBond Technologies
Cambridge, England, United Kingdom
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
StemBond's advanced hydrogel platform has demonstrated early validation as a tool for improving T cell activation and reducing exhaustion, with preclinical disease modeling applications in neurodegeneration and regenerative medicine. No clinical trial data is yet available; initial pilots with leading biotechs and pharma are ongoing.
- Therapeutic areas
- GastroenterologyOtherNeurologyOncology
- Modalities
- Hydrogel-based drug delivery therapyPlatform technologyStem cell therapy
- Industry
- Biotech
02
Partnerships
Cell and Gene Therapy CatapultBit.bioAxol Biosciences
Beyond the preview
Go deeper on StemBond Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemBond Technologies.